FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151513001> ?p ?o ?g. }

• W2151513001 endingPage "218" @default.
• W2151513001 startingPage "210" @default.
• W2151513001 abstract "Natalizumab disease-modifying therapy for relapsing-remitting multiple sclerosis (MS) is efficacious in randomized controlled trials. Few studies have estimated the association between real-world natalizumab persistence behavior and relapse-related outcomes.To (a) examine the impact of using natalizumab consistently (i.e., persistent) on relapse-related outcomes as compared with transitioning to inconsistent natalizumab use (i.e., nonpersistent) and (b) examine the impact of other treatment patterns on relapse-related outcomes for those who initiated natalizumab.Using the IMS PharMetrics Plus claims database (years 2006-2012), we identified MS subjects who initiated natalizumab (no natalizumab claims in year prior) and had at least 2 years of follow-up. Persistence in annual follow-up periods was defined as no 90-day or greater gap in natalizumab therapy. Relapse was an MS-related hospitalization or outpatient visit with intravenous or oral steroid burst claim within 7 days. Analyses compared observations based on changes in natalizumab persistence and natalizumab nonpersistence status from 1 year to the next (e.g., transitioning from persistent to nonpersistent), estimating differences in mean annual relapses and mean annual relapse-related costs.A total of 2,407 natalizumab initiators had at least 2 years of follow-up, yielding 4,770 year-to-year natalizumab treatment patterns where each subject contributed 1, 2, or 3 year-to-year treatment patterns. In the year prior, 3,187 treatment patterns were persistent; 731 (22.9%) of these transitioned to nonpersistence. The remaining 1,583 treatment patterns were nonpersistent in the year prior; 132 (8.3%) of these transitioned to persistence. Persistent to nonpersistent treatment patterns were associated with a mean relapse-rate increase of 0.23 (95% CI = 0.12, 0.35), and a mean increase in relapse-related costs of $1,346 (95% CI = $97, $2,595). Nonpersistent to persistent treatment patterns were associated with a mean relapse-rate decrease of -0.15 (95% CI = -0.32, 0.017) and a mean decrease in relapse-related costs of -$1,369 (95% CI = -$2,761, $23).Findings suggest that real-world persistent natalizumab users who become nonpersistent have statistically significant increases in annual relapses and relapse-related costs. Those who transition from nonpersistent to persistent have nonsignificant reductions in relapses and their associated costs." @default.
• W2151513001 created "2016-06-24" @default.
• W2151513001 creator A5018157909 @default.
• W2151513001 creator A5027368636 @default.
• W2151513001 creator A5035139473 @default.
• W2151513001 creator A5038587842 @default.
• W2151513001 creator A5045992434 @default.
• W2151513001 creator A5046218660 @default.
• W2151513001 creator A5056278530 @default.
• W2151513001 creator A5067266894 @default.
• W2151513001 date "2015-03-01" @default.
• W2151513001 modified "2023-09-25" @default.
• W2151513001 title "Increased Relapse Activity for Multiple Sclerosis Natalizumab Users Who Become Nonpersistent: A Retrospective Study" @default.
• W2151513001 cites W104010072 @default.
• W2151513001 cites W1581887055 @default.
• W2151513001 cites W1931564718 @default.
• W2151513001 cites W1943280741 @default.
• W2151513001 cites W1982508920 @default.
• W2151513001 cites W1984524168 @default.
• W2151513001 cites W1984705645 @default.
• W2151513001 cites W1991285554 @default.
• W2151513001 cites W1997159649 @default.
• W2151513001 cites W2000445173 @default.
• W2151513001 cites W2014094373 @default.
• W2151513001 cites W2020504874 @default.
• W2151513001 cites W2027732093 @default.
• W2151513001 cites W2036774081 @default.
• W2151513001 cites W2045690087 @default.
• W2151513001 cites W2049675062 @default.
• W2151513001 cites W2055269735 @default.
• W2151513001 cites W2059101486 @default.
• W2151513001 cites W2059889458 @default.
• W2151513001 cites W2061326496 @default.
• W2151513001 cites W2066800523 @default.
• W2151513001 cites W2067338532 @default.
• W2151513001 cites W2073757924 @default.
• W2151513001 cites W2076290890 @default.
• W2151513001 cites W2093042928 @default.
• W2151513001 cites W2094998560 @default.
• W2151513001 cites W2101710086 @default.
• W2151513001 cites W2129168200 @default.
• W2151513001 cites W2132555717 @default.
• W2151513001 cites W2133755641 @default.
• W2151513001 cites W2135834558 @default.
• W2151513001 cites W2139062201 @default.
• W2151513001 cites W2140240975 @default.
• W2151513001 cites W2148084100 @default.
• W2151513001 cites W2148455753 @default.
• W2151513001 cites W2155571619 @default.
• W2151513001 cites W2169394319 @default.
• W2151513001 cites W2288795182 @default.
• W2151513001 cites W33609267 @default.
• W2151513001 doi "https://doi.org/10.18553/jmcp.2015.21.3.210" @default.
• W2151513001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25726030" @default.
• W2151513001 hasPublicationYear "2015" @default.
• W2151513001 type Work @default.
• W2151513001 sameAs 2151513001 @default.
• W2151513001 citedByCount "6" @default.
• W2151513001 countsByYear W21515130012015 @default.
• W2151513001 countsByYear W21515130012017 @default.
• W2151513001 countsByYear W21515130012018 @default.
• W2151513001 countsByYear W21515130012022 @default.
• W2151513001 crossrefType "journal-article" @default.
• W2151513001 hasAuthorship W2151513001A5018157909 @default.
• W2151513001 hasAuthorship W2151513001A5027368636 @default.
• W2151513001 hasAuthorship W2151513001A5035139473 @default.
• W2151513001 hasAuthorship W2151513001A5038587842 @default.
• W2151513001 hasAuthorship W2151513001A5045992434 @default.
• W2151513001 hasAuthorship W2151513001A5046218660 @default.
• W2151513001 hasAuthorship W2151513001A5056278530 @default.
• W2151513001 hasAuthorship W2151513001A5067266894 @default.
• W2151513001 hasConcept C118552586 @default.
• W2151513001 hasConcept C126322002 @default.
• W2151513001 hasConcept C127413603 @default.
• W2151513001 hasConcept C167135981 @default.
• W2151513001 hasConcept C168563851 @default.
• W2151513001 hasConcept C187320778 @default.
• W2151513001 hasConcept C2780640218 @default.
• W2151513001 hasConcept C2781004633 @default.
• W2151513001 hasConcept C2781009140 @default.
• W2151513001 hasConcept C71924100 @default.
• W2151513001 hasConceptScore W2151513001C118552586 @default.
• W2151513001 hasConceptScore W2151513001C126322002 @default.
• W2151513001 hasConceptScore W2151513001C127413603 @default.
• W2151513001 hasConceptScore W2151513001C167135981 @default.
• W2151513001 hasConceptScore W2151513001C168563851 @default.
• W2151513001 hasConceptScore W2151513001C187320778 @default.
• W2151513001 hasConceptScore W2151513001C2780640218 @default.
• W2151513001 hasConceptScore W2151513001C2781004633 @default.
• W2151513001 hasConceptScore W2151513001C2781009140 @default.
• W2151513001 hasConceptScore W2151513001C71924100 @default.
• W2151513001 hasIssue "3" @default.
• W2151513001 hasLocation W21515130011 @default.
• W2151513001 hasLocation W21515130012 @default.
• W2151513001 hasOpenAccess W2151513001 @default.
• W2151513001 hasPrimaryLocation W21515130011 @default.
• W2151513001 hasRelatedWork W1982992122 @default.
• W2151513001 hasRelatedWork W1985660084 @default.

• next